All lobbying filings

AMNEAL PHARMACEUTICALS

AMNEAL PHARMACEUTICALS filed a Q2 report for AMNEAL PHARMACEUTICALS on July 20, 2026.

Lobbying for AMNEAL PHARMACEUTICALS · Pharmaceutical company

All filings by AMNEAL PHARMACEUTICALS · Everything AMNEAL PHARMACEUTICALS has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Expenses

$190,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

New Jersey

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Addressing drug shortages and enhancing domestic production of critical medicines Issues and proposed legislation related to long-term sustainability of access for patients to generic and biosimilar medicines, including but not limited to pharmaceutical supply chain security, drug shortages, biosimilar interchangeability, and PBM reform Issues related to Medicaid Generics Penalty Issues related to possible drug shortage of levothyroxine capsules Issues related to tariffs Appropriations for increasing domestic manufacturing of generic medicines Issues related to NDAA

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.